Summary

Eligibility
for people ages 18-75 (full criteria)
Location
at UCLA UCSD
Dates
study started
completion around

Description

Summary

A study to determine if BHV- 7000 is safe and tolerable in adults with refractory focal onset epilepsy

Official Title

A Phase 2, Global, Multicenter, Long-term Safety Study Designed to Assess the Safety and Tolerability of BHV-7000 in Subjects With Refractory Focal Onset Epilepsy

Keywords

Focal Epilepsy, Epilepsy, Seizure, Refractory Epilepsy, Partial Epilepsy, Partial Epilepsies, BHV-7000, BHV-7000 50 mg, BHV-7000 75 mg

Eligibility

Locations

Details

Status
accepting new patients by invitation only
Start Date
Completion Date
(estimated)
Sponsor
Biohaven Therapeutics Ltd.
ID
NCT06443463
Phase
Phase 2 Epilepsy Research Study
Study Type
Interventional
Participants
Expecting 660 study participants
Last Updated